Topical tranexamic acid versus autotransfusion after total knee arthroplasty. 2016

Y Guzel, and O T Gurcan, and U H Golge, and T C Dulgeroglu, and H Metineren
Ordu University Medical School, Turkey.

To compare the use of topical tranexamic acid (TXA) with postoperative autologous transfusion (PAT) in terms of blood loss, need for allogeneic blood transfusion, and cost-effectiveness. Records of 25 men and 125 women (mean age, 67 years) who underwent primary unilateral total knee arthroplasty (TKA) and were randomised to the PAT group (n=50), topical TXA group (n=50), or routine drainage group (control) [n=50] were reviewed. Pre- and post-operative haemoglobin level, total postoperative drainage volume, and the need for allogeneic blood transfusion were recorded. The 3 groups were comparable in terms of age, gender, and preoperative haemoglobin level. The total postoperative drainage volume was lower in the TXA group than the PAT or routine drainage groups (174.48 vs. 735 vs. 760 ml, p<0.001). The postoperative haemoglobin level was lower in the routine drainage group than the PAT or TXA groups on day 1 (11.67 vs. 12.33 vs. 12.40 g/dl, p<0.001) and day 3 (9.9 vs. 10.7 vs. 11.14 g/dl, p<0.001). The number of patients who received allogeneic blood transfusion was higher in the routine drainage group (12 and 4 patients received 1 and 2 units of blood, respectively) than the PAT group (4 patients received 1 unit of blood) or the TXA group (none required transfusion) [p<0.001], and the respective total transfusion cost was $1200, $240, and $0. The total cost was lowest in the TXA group followed by the routine drainage group and PAT group ($200 vs. $1200 vs. $12 390). No patient developed acute infection, deep venous thrombosis, pulmonary embolism, myocardial infarction, or stroke. Compared with PAT, topical TXA was more cost-effective and resulted in less total postoperative drainage volume and less need for allogeneic blood transfusion.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001804 Blood Transfusion, Autologous Reinfusion of blood or blood products derived from the patient's own circulation. (Dorland, 27th ed) Autotransfusion,Autologous Blood Transfusion,Autologous Blood Transfusions,Blood Transfusions, Autologous,Transfusion, Autologous Blood,Transfusions, Autologous Blood,Autotransfusions
D003362 Cost-Benefit Analysis A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. In contrast a cost effectiveness in general compares cost with qualitative outcomes. Cost and Benefit,Cost-Benefit Data,Benefits and Costs,Cost Benefit,Cost Benefit Analysis,Cost-Utility Analysis,Costs and Benefits,Economic Evaluation,Marginal Analysis,Analyses, Cost Benefit,Analysis, Cost Benefit,Analysis, Cost-Benefit,Analysis, Cost-Utility,Analysis, Marginal,Benefit and Cost,Cost Benefit Analyses,Cost Benefit Data,Cost Utility Analysis,Cost-Benefit Analyses,Cost-Utility Analyses,Data, Cost-Benefit,Economic Evaluations,Evaluation, Economic,Marginal Analyses
D004322 Drainage The removal of fluids or discharges from the body, such as from a wound, sore, or cavity.
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000933 Antifibrinolytic Agents Agents that prevent fibrinolysis or lysis of a blood clot or thrombus. Several endogenous antiplasmins are known. The drugs are used to control massive hemorrhage and in other coagulation disorders. Antifibrinolysin,Antifibrinolysins,Antifibrinolytic,Antifibrinolytic Agent,Antiplasmin,Antiplasmins,Antifibrinolytics,Plasmin Inhibitor,Plasmin Inhibitors,Agent, Antifibrinolytic,Agents, Antifibrinolytic,Inhibitor, Plasmin,Inhibitors, Plasmin
D014148 Tranexamic Acid Antifibrinolytic hemostatic used in severe hemorrhage. AMCHA,AMCA,Amchafibrin,Anvitoff,Cyklokapron,Exacyl,KABI 2161,Spotof,Transamin,Ugurol,t-AMCHA,trans-4-(Aminomethyl)cyclohexanecarboxylic Acid

Related Publications

Y Guzel, and O T Gurcan, and U H Golge, and T C Dulgeroglu, and H Metineren
March 2015, The Journal of arthroplasty,
Y Guzel, and O T Gurcan, and U H Golge, and T C Dulgeroglu, and H Metineren
January 2017, Journal of orthopaedic surgery (Hong Kong),
Y Guzel, and O T Gurcan, and U H Golge, and T C Dulgeroglu, and H Metineren
January 2020, The Orthopedic clinics of North America,
Y Guzel, and O T Gurcan, and U H Golge, and T C Dulgeroglu, and H Metineren
November 2017, Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA,
Y Guzel, and O T Gurcan, and U H Golge, and T C Dulgeroglu, and H Metineren
January 1996, Orthopedics,
Y Guzel, and O T Gurcan, and U H Golge, and T C Dulgeroglu, and H Metineren
June 2018, BMC musculoskeletal disorders,
Y Guzel, and O T Gurcan, and U H Golge, and T C Dulgeroglu, and H Metineren
August 2014, The Journal of arthroplasty,
Y Guzel, and O T Gurcan, and U H Golge, and T C Dulgeroglu, and H Metineren
November 2015, Orthopedics,
Y Guzel, and O T Gurcan, and U H Golge, and T C Dulgeroglu, and H Metineren
October 2016, Medicine,
Y Guzel, and O T Gurcan, and U H Golge, and T C Dulgeroglu, and H Metineren
January 2021, Acta ortopedica brasileira,
Copied contents to your clipboard!